A randomised controlled trial of ranibizumab with and without ketorolac eyedrops for exudative age-related macular degeneration

Andrea Russo, Ciro Costagliola, Luisa Delcassi, Mario R. Romano, Francesco Semeraro

Research output: Contribution to journalArticlepeer-review

Abstract

Aims: To evaluate whether ketorolac eyedrops and ranibizumab intravitreal injections would provide additional benefit over ranibizumab alone in the treatment of choroidal neovascularisation (CNV). Methods: This was a pilot study of eyes with new-onset CNV. A total of 56 patients were enrolled consecutively and randomised in a 1:1 ratio to receive combination treatment with intravitreal ranibizumab and topical ketorolac (group 1) or ranibizumab alone (group 2). All patients received monthly 0.5-mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered in accordance with the standard of care. Group 1 patients also self-administered one drop of ketorolac three times a day for 6 months. All patients were followed up for 6 months. Results: At 6 months, both groups showed a significant improvement in best-corrected visual acuity (both, p

Original languageEnglish
Pages (from-to)1273-1276
Number of pages4
JournalBritish Journal of Ophthalmology
Volume97
Issue number10
DOIs
Publication statusPublished - Oct 2013

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Fingerprint Dive into the research topics of 'A randomised controlled trial of ranibizumab with and without ketorolac eyedrops for exudative age-related macular degeneration'. Together they form a unique fingerprint.

Cite this